- Home
- KBDC vs SLS Comparison
KBDC vs SLS Comparison
Compare KBDC & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KBDC | SLS |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.7M | 924.5M |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | KBDC | SLS |
|---|---|---|
| Price | $13.99 | $7.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $15.50 | $10.00 |
| AVG Volume (30 Days) | 226.4K | ★ 9.3M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 13.16% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $193.84 | N/A |
| Revenue Next Year | $9.00 | $110.98 |
| P/E Ratio | $32.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.06 | $1.39 |
| 52 Week High | $16.28 | $9.51 |
Technical Indicators
Market Signals| Indicator | KBDC | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 50.91 |
| Support Level | $13.52 | $3.72 |
| Resistance Level | $14.30 | $9.51 |
| Average True Range (ATR) | 0.33 | 0.70 |
| MACD | -0.07 | -0.22 |
| Stochastic Oscillator | 5.59 | 20.72 |
Price Performance
Historical ComparisonAbout KBDC Kayne Anderson BDC Inc.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.